PDCD1 and melanoma: In previous studies, patients with primary or metastatic urothelial cancer, breast cancer, and melanoma were treated with single or combined monoclonal antibodies against PD-L1, PD-1, and CTLA-4, and the clinical outcomes suggest a protective role for TAP1 [25–28].